ArticleAmerican journal of translational research2025
Enhanced efficacy and safety of combining Aidi injection with megestrol acetate for endometrial cancer treatment.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the therapeutic efficacy of Aidi injection combined with megestrol acetate (MA) in patients with endometrial cancer (EC) and to investigate its effects on serum biomarkers, including human epididymis protein 4 (HE4), carcinoembryonic antigen (CEA), and cancer antigen 125 (CA125).
methodsA retrospective analysis was conducted on 120 EC patients treated at Luoyang Central Hospital between January 2023 and January 2024. Patients were categorized into two groups based on their treatment regimen: the MA group (n=60) that received chemotherapy combined with oral MA, and the Aidi group (n=60) that received additional Aidi injection alongside the regimen used in the MA group. Clinical outcomes assessed included overall treatment efficacy, maximum lesion size, survival status, tumor marker levels, serological indicators, and adverse reaction rates (ARR).
resultsThe Aidi group demonstrated superior outcomes compared to the MA group, with significantly higher objective response rates (ORR) and disease control rates (DCR) (P<0.05). Additionally, the Aidi group demonstrated a greater reduction of maximum lesion diameter (P<0.001), improved quality of life (P<0.001), and lower serum concentrations of HE4, CEA, and CA125 (P<0.001). In addition, levels of connective tissue growth factor (CTGF), angiopoietin-2 (Ang-2), prolactin (PRL), and ARR were significantly reduced (P<0.05).
conclusionAidi injection combined with MA provided a promising therapeutic strategy for EC. This regimen effectively inhibited tumor progression, improveed quality of life, and decreased serum tumor marker levels (HE4, CEA, and CA125), supporting its potential for broader clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.